Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

Abbott Laboratories closed 10.57% short of its 52-week high of $141.23, which the company reached on March 4th.

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few ...

In this article, we will take a look into Abbott Laboratories's (NYSE:ABT) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

Today, Benzinga 's options scanner spotted 10 uncommon options trades for Abbott Laboratories. This isn't normal. The overall ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT – Research Report) and ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories (NYSE:ABT). And retail traders should know. We noticed this today when the trades showed up on publicly ...

In the last year, many Abbott Laboratories ( NYSE:ABT ) insiders sold a substantial stake in the company which may ...